Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × sapanisertib × Sarcoma × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5 Breast 5 Lymphoid 4 Gynecologic 4 Thoracic 3 Plasma cell 3 Other hematologic neoplasm 2 Sarcoma 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 CNS 1

Conditions

Interventions

Cyclophosphamide 93 Doxorubicin 92 Radiotherapy 87 Temozolomide 69 Filgrastim 58 Ifosfamide 55 Bevacizumab 55 Etoposide 48 Gemcitabine 44 Imatinib Mesylate 43 Vincristine 40 pembrolizumab 35 pazopanib 34 Peripheral Blood Stem Cell Transplantation 31 Methotrexate 30 Carboplatin 30 fludarabine phosphate 29 Nivolumab 29 Irinotecan 29 Cisplatin 28 Paclitaxel 26 Melphalan 26 Magnetic Resonance Spectroscopy 25 Docetaxel 25 Busulfan 25 Trabectedin 24 apatinib 22 Sirolimus 21 Antilymphocyte Serum 21 Specimen Handling 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Fox Chase Cancer Center

Phase 2 Terminated

6 enrolled 10 charts

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡